Shield Therapeutics plc (AIM:STX)
London
· Delayed Price · Currency is GBP · Price in GBX 8.70
-0.15 (-1.69%)
Apr 28, 2026, 4:14 PM GMT
Shield Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 49.7 | 32.18 | 13.09 | 5.5 | 2.06 | Upgrade
|
| Revenue Growth (YoY) | 54.45% | 145.93% | 137.95% | 167.36% | -85.50% | Upgrade
|
| Cost of Revenue | 26.66 | 17.25 | 9.06 | 3.04 | 1.33 | Upgrade
|
| Gross Profit | 23.04 | 14.93 | 4.03 | 2.46 | 0.73 | Upgrade
|
| Selling, General & Admin | 31.59 | 36.01 | 37.96 | 33.65 | 27.28 | Upgrade
|
| Research & Development | 1.54 | 1.89 | 1.81 | 1.32 | 1.08 | Upgrade
|
| Other Operating Expenses | -0.04 | -0.1 | -4.41 | -0.86 | -0.15 | Upgrade
|
| Operating Expenses | 33.09 | 37.8 | 35.36 | 34.1 | 28.21 | Upgrade
|
| Operating Income | -10.05 | -22.87 | -31.33 | -31.65 | -27.48 | Upgrade
|
| Interest Expense | -7.42 | -3.87 | -1.02 | -0.4 | - | Upgrade
|
| Interest & Investment Income | 0.33 | 0.27 | 0.52 | 0.04 | 0.02 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -0.08 | -0.54 | 0.85 | 0.52 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | -0 | -0.08 | -0.01 | Upgrade
|
| EBT Excluding Unusual Items | -17.14 | -26.56 | -32.38 | -31.24 | -26.96 | Upgrade
|
| Asset Writedown | - | - | - | -18.11 | - | Upgrade
|
| Pretax Income | -17.14 | -26.56 | -32.38 | -49.34 | -26.96 | Upgrade
|
| Income Tax Expense | 0.51 | 0.63 | 0.92 | 0.45 | -0.31 | Upgrade
|
| Earnings From Continuing Operations | -17.66 | -27.18 | -33.29 | -49.79 | -26.65 | Upgrade
|
| Net Income | -17.66 | -27.18 | -33.29 | -49.79 | -26.65 | Upgrade
|
| Net Income to Common | -17.66 | -27.18 | -33.29 | -49.79 | -26.65 | Upgrade
|
| Shares Outstanding (Basic) | 883 | 783 | 723 | 233 | 204 | Upgrade
|
| Shares Outstanding (Diluted) | 883 | 783 | 723 | 233 | 204 | Upgrade
|
| Shares Change (YoY) | 12.77% | 8.33% | 209.85% | 14.08% | 74.36% | Upgrade
|
| EPS (Basic) | -0.02 | -0.03 | -0.05 | -0.21 | -0.13 | Upgrade
|
| EPS (Diluted) | -0.02 | -0.03 | -0.05 | -0.21 | -0.13 | Upgrade
|
| Free Cash Flow | -3.4 | -6.81 | -37.37 | -22.66 | -25.23 | Upgrade
|
| Free Cash Flow Per Share | -0.00 | -0.01 | -0.05 | -0.10 | -0.12 | Upgrade
|
| Gross Margin | 46.36% | 46.39% | 30.78% | 44.70% | 35.48% | Upgrade
|
| Operating Margin | -20.22% | -71.08% | -239.44% | -575.49% | -1336.01% | Upgrade
|
| Profit Margin | -35.52% | -84.47% | -254.44% | -905.42% | -1295.46% | Upgrade
|
| Free Cash Flow Margin | -6.85% | -21.15% | -285.56% | -411.98% | -1226.73% | Upgrade
|
| EBITDA | -8.94 | -22.38 | -31.08 | -29.67 | -25.39 | Upgrade
|
| EBITDA Margin | -17.98% | -69.56% | -237.51% | - | - | Upgrade
|
| D&A For EBITDA | 1.12 | 0.49 | 0.25 | 1.97 | 2.09 | Upgrade
|
| EBIT | -10.05 | -22.87 | -31.33 | -31.65 | -27.48 | Upgrade
|
| EBIT Margin | -20.22% | -71.08% | -239.44% | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.